Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | AGER | Q15109 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481578 | 1.00 | PPARA (0.41) | PPARAALBFFAR4FFAR1CYSLTR2 | |
| SCHEMBL1480837 | 0.95 | FFAR1 (0.42) | PPARAALBFFAR4FFAR1CYSLTR2 | |
| SCHEMBL1480840 | 0.95 | FFAR1 (0.42) | PPARAALBFFAR4FFAR1CYSLTR2 | |
| SCHEMBL1480599 | 0.93 | FFAR4 (0.41) | PPARAFFAR4FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL1480598 | 0.93 | FFAR4 (0.41) | PPARAFFAR4FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL1481594 | 0.92 | FFAR4 (0.44) | PPARAALBFFAR4FFAR1CYSLTR2 | |
| SCHEMBL12735962 | 0.92 | PPARG (0.43) | PPARAALBFFAR4FFAR1CYSLTR2 | |
| SCHEMBL1481591 | 0.92 | FFAR4 (0.44) | PPARAALBFFAR4FFAR1CYSLTR2 | |
| SCHEMBL1480709 | 0.92 | FFAR4 (0.39) | PPARAALBFFAR4FFAR1CYSLTR2 | |
| SCHEMBL1480711 | 0.92 | FFAR4 (0.39) | PPARAALBFFAR4FFAR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004071447-A9 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | PPARA 2236/4885ALB 1690/4885FFAR4 2604/4885 |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | PPARA 2606/4885ALB 1100/4885FFAR4 2384/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | PPARA 2606/4885ALB 1100/4885FFAR4 2384/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | PPARA 2236/4885ALB 1690/4885FFAR4 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.